Positive responses have been observed with antibodies targeting PD-1 (pembrolizumab and nivolumab), PD-L1 (durvalumab and atezolizumab) and CTLA-4 (ipilimumab), and the clinical applications of these checkpoint inhibitors in various combination therapies for treating colon cancer are ongoing [11–16]. This evidence concerns the gene CD274 and colonic neoplasm.